; The mission of the Protocol Review and Monitoring System (PRMS) is to provide internal oversight of all cancer clinical trials conducted at the OHSU Knight Cancer Institute to ensure both scientific integrity and the protection of human subjects through the course of the clinical research process. The PRMS includes initial scientific protocol review, real-time monitoring of protocol activity, monthly cumulative report review, annual review and final review. All components of the PRMS at the Knight are the responsibility of the Clinical Research Review Committee (CRRC). The CRRC is charged by the Knight Cancer Institute Director to ensure that all clinical trials and cancer-related research conducted at the Institute are: 1) scientifically meritorious;2) appropriately designed and statistically validated;3) feasible for completion within the specified time frame;4) to ensure clinical trial compliance with FDA and NIH guidelines;and, 5) compatible with the priorities, goals, and interests of the Institute. The functions of the CRRC are independent of the OHSU Institutional Review Board (IRB) and the Data and Safety Monitoring Committee (DSMC).

Public Health Relevance

The mission of the Protocol Review and Monitoring System (PRMS) is to provide internal oversight of all cancer clinical trials conducted at the OHSU Knight Cancer Institute to ensure both scientific integrity and the protection of human subjects through the course of the clinical research process.

Agency
National Institute of Health (NIH)
Type
Center Core Grants (P30)
Project #
5P30CA069533-17
Application #
8712385
Study Section
Subcommittee B - Comprehensiveness (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
17
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Oregon Health and Science University
Department
Type
DUNS #
City
Portland
State
OR
Country
United States
Zip Code
97239
Chen, Yiyi; Chen, Zunqiu; Mori, Motomi (2016) A new statistical decision rule for single-arm phase II oncology trials. Stat Methods Med Res 25:118-32
Pati, Shibani; Potter, Daniel R; Baimukanova, Gyulnar et al. (2016) Modulating the endotheliopathy of trauma: Factor concentrate versus fresh frozen plasma. J Trauma Acute Care Surg 80:576-84; discussion 584-5
Coleman, Daniel J; Van Hook, Kathryn; King, Carly J et al. (2016) Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor. Oncotarget 7:40690-40703
Tsikitis, Vassiliki L; Potter, Amiee; Mori, Motomi et al. (2016) MicroRNA Signatures of Colonic Polyps on Screening and Histology. Cancer Prev Res (Phila) 9:942-949
Wiedmeier, Julia Erin; Kato, Catherine; Zhang, Zhenzhen et al. (2016) Clonal hematopoiesis as determined by the HUMARA assay is a marker for acquired mutations in epigenetic regulators in older women. Exp Hematol 44:857-865.e5
Young, John I; Mongoue-Tchokote, Solange; Wieghard, Nicole et al. (2016) Treatment and Survival of Small-bowel Adenocarcinoma in the United States: A Comparison With Colon Cancer. Dis Colon Rectum 59:306-15
Goodspeed, Andrew; Heiser, Laura M; Gray, Joe W et al. (2016) Tumor-Derived Cell Lines as Molecular Models of Cancer Pharmacogenomics. Mol Cancer Res 14:3-13
Ebrahim, Seham; Avenarius, Matthew R; Grati, M'hamed et al. (2016) Stereocilia-staircase spacing is influenced by myosin III motors and their cargos espin-1 and espin-like. Nat Commun 7:10833
Cambronne, Xiaolu A; Stewart, Melissa L; Kim, DongHo et al. (2016) Biosensor reveals multiple sources for mitochondrial NAD⁺. Science 352:1474-7
Zhang, Zhenzhen; Garzotto, Mark; Beer, Tomasz M et al. (2016) Effects of ω-3 Fatty Acids and Catechins on Fatty Acid Synthase in the Prostate: A Randomized Controlled Trial. Nutr Cancer 68:1309-1319

Showing the most recent 10 out of 188 publications